1491144-00-3
Chemical Structure
Avacincaptad pegol sodium
Synonym(s): ARC1905
- CAS No.: 1491144-00-3
- Formula:N/A
- Molecular Weight:53500 (Approximately)
IUPAC Name: benzyl 6-oxo-5-oxa-2,7-diazaspiro[3.4]octane-2-carboxylate
SMILES: [Avacincaptad pegol sodium]
Biological Activity: Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Avacincaptad pegol sodium | 92.50% | Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Joshua Ong, et al. The Complement System as a Therapeutic Target in Retinal Disease. Medicina (Kaunas). 2024 Jun 5;60(6):945. [Content Brief]
- [2]. Yiming Li, et al. Targeting both C5 and HTRA1 provides additional rescue effect in NaIO3-induce GA model. IOVS. June 2024, Vol.65, OD68.
- [3]. Aira Sarkar, et al. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discov Today. 2022 Aug;27(8):2322-2332. [Content Brief]
- [4]. Padma Sundaram, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013 Jan 23;48(1-2):259-71. [Content Brief]
Keywords
